What this is
- This trial compared analgesia-based sedation using remifentanil to standard hypnotic-based sedation in neuro-intensive care unit patients.
- Patients aged 18-80 with acute brain injuries requiring mechanical ventilation were randomized to receive either remifentanil or standard sedatives.
- The study evaluated safety, efficacy, and time to neurological assessment, focusing on sedation quality and patient recovery.
Essence
- Remifentanil-based sedation allowed for faster and more predictable emergence for neurological assessments compared to hypnotic-based sedation. It was well tolerated and provided comparable safety profiles.
Key takeaways
- Analgesia-based sedation with remifentanil led to shorter mean neurological assessment times compared to fentanyl and morphine. Patients were assessed 0.3 hours and 0.41 hours earlier, respectively.
- Patients receiving remifentanil were extubated significantly faster than those treated with morphine (1.0 hour vs. 1.93 hours). No significant difference was noted between remifentanil and fentanyl.
- Seventy-eight percent of healthcare providers rated remifentanil's performance in facilitating neurological assessments as very good or excellent, compared to 25% for fentanyl and 8% for morphine.
Caveats
- The study's open-label design may introduce bias in the assessment of outcomes. The lack of consistent differences in later days could indicate reduced statistical power due to fewer patients.
- Adverse events were slightly more frequent in the remifentanil group, although most were isolated incidents and not significantly different from the other groups.
Definitions
- Sedation-Agitation Scale (SAS): A scale used to assess sedation levels, ranging from 1 (not rousable) to 3 (sedated but responsive).
- Pain Intensity (PI): A scale measuring pain severity from 1 (no pain) to 6 (worst possible pain).
AI simplified
Introduction
Fentanyl and morphine are commonly used in the neuro-intensive care unit (neuro-ICU) setting. However, when administered over several days, the elimination of these traditional opioids can become prolonged as a result of redistribution and accumulation. This can result in unpredictable and/or delayed emergence from sedation when the regimen is discontinued to allow neurological assessments. Propofol and midazolam are the most commonly used hypnotic agents because of their effectiveness and short elimination half-lives [1,2]. Propofol is usually preferred during the first 2β3 days after admission to ICU because its use allows for frequent assessments of progression of neurological damage or recovery. If sedation is to be extended beyond 3 days, propofol is often replaced with midazolam on the basis of its lower cost. With these hypnotic agents, the risk for accumulation and unpredictable or delayed emergence is potentially smaller than with traditional opioids. In view of this, the opioid dose is usually minimised, with the hypnotic agent adjusted to maintain patient comfort. Thus, currently used sedative regimens could be considered to be predominantly hypnotic-based treatment regimens.
Remifentanil hydrochloride is a potent, selective ΞΌ-opioid receptor agonist, for the provision of analgesia in mechanically ventilated critically ill patients. Remifentanil has an onset of action of about 1 min and quickly achieves steady state. Unlike existing opioids, however, it is rapidly metabolised by non-specific blood and tissue esterases [3] to a clinically inactive metabolite. This results in an elimination half-life of less than 10 min, which is independent of the duration of infusion [4]. These characteristics make remifentanil very easy to titrate to effect and allow administration at higher doses than are normally used with traditional opioids without concerns about accumulation and unpredictable and/or delayed recovery. Synergistic interaction between remifentanil and sedatives results in sedative-sparing effects of volatile [5] and intravenous [6] agents.
When ventilation is controlled, remifentanil does not cause an increase in intracranial pressure when administered to patients undergoing craniotomy [7]. The cerebral haemodynamic effects of remifentanil compared with those of alfentanil [8] and fentanyl [9] are similar; remifentanil also has a safety profile similar to that of other opioids [8-10]. The predictable offset of action allows a rapid emergence from anaesthesia without the need for naloxone [9]. Other studies have confirmed that remifentanil can provide good haemodynamic control during particularly stimulating stages of craniotomy procedures yet still provide rapid and predictable emergence from anaesthesia [11,12]. The usefulness of remifentanil in patients undergoing awake craniotomy has also been demonstrated [13,14].
This study was designed to compare the safety and efficacy of analgesia-based sedation with conventional hypnotic-based sedation in patients with brain injuries requiring sedation during mechanical ventilation. Remifentanil was to be initiated and titrated to provide optimal sedation and analgesia before the addition of propofol (days 1β3) or midazolam (days 4 and 5) according to a predefined dosing algorithm. This type of regimen has already been shown to be both achievable and effective in post-surgical ICU patients [15]. The hypnotic-based treatment regimen required the opioid (fentanyl or morphine) and propofol (days 1β3) or midazolam (days 4 and 5) to be started simultaneously and then titrated to provide optimal sedation and analgesia, according to standard clinical practice.
Methods
This randomised, open-label, observational, parallel group study was conducted at 17 hospitals in six countries in Europe (4 in Greece, 4 in Spain, 3 in Belgium, 3 in The Netherlands, 2 in Germany, 1 in Austria). The study was conducted in accordance with good clinical practice and with the guidelines set out in the Declaration of Helsinki. After local and national ethics committee approvals, a total of 161 patients with acute brain injuries or who had undergone intracranial surgery were recruited. Informed consent or assent was obtained from all patients or their legal representatives. Patients were randomised on a 2:1:1 basis to receive either an analgesia-based treatment regimen in which patients initially received only remifentanil (n = 84), which was then titrated to provide optimal analgesia and sedation before the addition of a hypnotic agent (if required), or a hypnotic-based treatment regimen in which patients received a hypnotic agent and either fentanyl (n = 37) or morphine (n = 40) for analgesia and sedation, which were administered simultaneously and then titrated to response. For all three treatment groups, on days 1β3 the hypnotic agent was propofol, and on days 4 and 5 propofol was replaced with midazolam.
Patients with an acute, severe neurological insult or injury or who had undergone elective or emergency neurosurgery were eligible for entry into the study if they were aged 18β80 years, weighed 120 kg or less, had been admitted into the ICU within the past 24 hours, were intubated and were expected to require mechanical ventilation for 1β5 days. Patients were excluded from the study if they had or were likely to require one of the following: long-acting (or continuous administration of) neuromuscular blocking drugs to facilitate mechanical ventilation during the study period, barbiturate administration before or during the study period, or an epidural block during the maintenance or extubation phases of the study (see below). Any patients who failed to demonstrate signs of recovery or responsiveness within 6 hours of stopping any analgesia/sedation regimen in use at the time of screening for study entry were excluded from the study. Patients who were likely to require a tracheostomy with spontaneous ventilation within 5 days of starting the study drug treatment were excluded. Patients were also excluded if they had suffered severe, associated traumatic injury, if they had a neurological condition that might affect the ability to assess their SedationβAgitation Scale (SAS) score [16], if they were admitted for status epilepticus or if they had moderate or severe renal impairment (predicted creatinine clearance of less than 50 ml min-1). Patients with a history of allergy to opioids, benzodiazepines or propofol or of alcohol or drug abuse were also excluded from the study. Pregnant or lactating women were excluded from the study.
The treatment period comprised the time interval from the start of study drug administration until their permanent discontinuation, and was composed of three phases: first, the maintenance phase, from the start of the study drugs up to 5 days of treatment with the study drugs or until withdrawal of the patient or start of the extubation phase; second, the extubation phase, from the time that the patient was eligible for extubation until the time of actual extubation; and third, the post-extubation phase, from the time that the patient was extubated until the study drugs were discontinued.
In addition, there was a post-treatment period: from the time of discontinuation of the study drugs until 24 hours later or until discharge from ICU, whichever occurred first, and a follow-up period from 24 hours after stopping infusion of the study drugs until either ICU discharge or the end of day 7 after the start of study drugs, or death, whichever event occurred first.
Treatment protocol
The goal of treatment was to maintain each patient at an optimal level of sedation, based on an SAS score in the range 1β3 (Table 1) without clinically significant pain for the 5 days of the study period or until the start of the extubation process, whichever occurred first. Pain was assessed with a six-point Pain Intensity (PI) scale, in which 1 was no pain, 2 was mild pain, 3 was moderate pain, 4 was severe pain, 5 was very severe pain, and 6 was worst possible pain. If the patient could be roused they were asked if they had any pain. If the patient was unconscious, raised heart rate (HR) and/or blood pressure were used as indicators that the patient had moderate or worse pain. Clinically significant pain was defined as a score of 3 or more. SAS and PI scores were assessed by the investigator or study nurse throughout the treatment period.
On completion of the treatment period (that is, from the extubation phase onwards), sedation and pain relief were administered at the discretion of the investigator and in accordance with local practice.
| Score | Definition | Description |
|---|---|---|
| 1 | Patient is not rousable | Patient may move or grimace minimally to stimuli but does not communicate or follow commands |
| 2 | Patient is very sedated | Patient can be roused by physical stimuli but does not communicate or follow commands; may move spontaneously |
| 3 | Patient is sedated | Patient is difficult to rouse, awakens to verbal stimuli or gentle shaking but drifts off again; will follow simple commands |
Remifentanil-based treatment
To assess the remifentanil-based regimen to provide optimal patient comfort, patients were treated in accordance with a modified version of a previously reported dosing algorithm [15,17] in which they received an initial infusion of remifentanil, which was titrated to response, before the propofol infusion was started. The remifentanil infusion was started at an initial rate of 9 ΞΌg kg-1 h-1 and was increased in increments of at least 1.5 ΞΌg kg-1 h-1 at intervals of 5β10 min depending on clinical need or severity of illness up to 18 ΞΌg kg-1 h-1. If the target scores for patient comfort (SAS = 1β3; PI = 1β2) were not achieved with remifentanil alone (infusion rate at 18 ΞΌg kg-1 h-1), additional sedation was provided by administering a bolus dose of propofol (up to 0.5 mg kg-1) and/or a propofol infusion starting at a rate of 0.5 mg kg-1 h-1, at the investigator's discretion. If the target SAS range of 1β3 was still not achieved, the patient received incremental increases in the remifentanil infusion to a maximum rate of 60 ΞΌg kg-1 h-1 and/or additional boluses and/or increases in the infusion rate of propofol up to a maximum dose of 4 mg kg-1 h-1 to attain and then maintain optimum analgesia and sedation. The remifentanil infusion rate was increased in preference to propofol when more intense analgesia was required.
The remifentanil/propofol treatment regimen was maintained for the first 3 days of the study. Patients who required analgesia and sedation beyond study day 3 had their propofol treatment discontinued and replaced with midazolam (recommended doses: bolus doses 0.01β0.05 mg kg-1, infusions 0.03β0.3 mg kg-1 h-1).
Hypnotic-based treatment
For the patients randomised to receive fentanyl or morphine, optimal analgesia and sedation as described above were achieved in accordance with routine local practice for a hypnotic-based treatment regimen. As with the remifentanil treatment group, in the patients who continued to require analgesia and sedation beyond day 3, propofol was discontinued and replaced with midazolam in accordance with local transitioning protocols. The infusion rates of fentanyl and morphine and bolus doses and infusion rates of propofol and midazolam were not specified in the protocol but were those that were used as part of routine clinical practice at each investigating site.
Bolus doses of remifentanil, morphine or fentanyl were not administered during the maintenance period of the study, to avoid and minimise any systemic or intracranial haemodynamic side effects.
If a patient in any of the three treatment groups showed signs of hypotension (more than 25% fall in mean arterial pressure [MAP] from baseline) or bradycardia (HR less than 40 beats per minute (bpm) for less than 1 min, less than 60 bpm for more than 1 min), the opioid and/or hypnotic drug infusion rates were to be reduced as considered appropriate by the individual investigator, and the patient was reassessed 10 min later.
Patient monitoring
All patients were monitored intensively throughout the study. Baseline Glasgow Coma Score (GCS), SAS, PI, MAP and HR were recorded before the administration of study drugs. When available, intra-cranial pressure (ICP) and cerebral perfusion pressure (CPP) were also recorded. SAS, PI, MAP, HR, ICP and CPP were then recorded at the time of any changes in study drug infusion rates or bolus dosing and at 10 min intervals afterwards until adequate SAS and PI scores were attained. Once target SAS and PI scores were attained, haemodynamic monitoring was performed at 1β4 hour intervals. In addition, haemodynamic parameters were recorded at the start of down-titrations of study drugs for neurological assessment of patients and when the assessments were completed. SAS, PI, MAP, HR, ICP and CPP were also recorded at the start of and at the time of adequate transitioning from propofol to midazolam at the end of day 3 and if a patient was extubated before day 5 of the study treatment period. These parameters were also recorded at the start of the final transition to an alternative analgesia/sedation regimen at the end of study day 5, at 20 min intervals after each down-titration of the remifentanil infusion as part of this process, at 30 and 60 min after the termination of the infusion and at final transition to an alternative opioid. Patients were continuously assessed for the occurrence of adverse events until 24 hours after permanent discontinuation of the study drugs, or until ICU discharge if this occurred earlier. Serious adverse events were defined as adverse events that resulted in any of the following outcomes: death, life-threatening event, prolongation of hospitalisation, or a disability or incapacity. Important medical events that did not result in death or were not life-threatening were considered serious adverse events when, on the basis of appropriate medical judgement, they jeopardised the patient and required medical or surgical intervention to prevent one of the outcomes listed above.
Neurological assessments
The level of sedation was reduced to allow neurological assessment according to individual clinical need; however, there was at least one neurological assessment in any 24-hour study period. The first assessment did not take place until at least 6 hours after starting the study drugs. The efficacy of the study treatment regimens was assessed by comparing the respective neurological assessment time intervals, defined as the time from the start of the first down-titration or withholding of the administration of either the opioid or the hypnotic component of the treatment regimen to the time at which the neurological assessment was completed.
In the remifentanil treatment group, the remifentanil infusion was reduced in decrements of not more than 25% of the current rate at 10 min intervals to a level that permitted neurological assessment of the patient to be performed (Fig. 1). This was to provide a smooth offset of analgesia. Any down-titration of the co-administered hypnotic agent was performed secondary to the initial reduction in the remifentanil infusion in decrements at the investigator's discretion. Once neurological assessment was completed, the remifentanil infusion was increased in increments of at least 1.5 ΞΌg kg-1 h-1 until the pre-assessment infusion rate and/or target SAS and PI scores were attained. Where appropriate, the concomitant hypnotic agent was simultaneously increased to the pre-assessment infusion rate and/or until the target SAS and PI scores were attained, at the investigator's discretion. For patients in the fentanyl or morphine groups, down-titration or discontinuation of the opioid and/or hypnotic agents for neurological assessments (and subsequent up-titration afterwards) were made at the investigator's discretion and in accordance with routine practice at the investigational site.
Downward titration of remifentanil for neurological assessment.
Extubation within the 5-day study period
All patients continued on study treatment until they were judged by the investigator to be eligible to begin the extubation process. To allow for smooth emergence from the effects of remifentanil and adequate time for transitioning to alternative analgesia, the remifentanil infusion rate was decreased every 10β20 min over a period of up to 1 hour to an infusion rate of 6 ΞΌg kg-1 h-1. The number of stages and the size of each reduction in the infusion rate were at the individual investigator's discretion. After extubation, the remifentanil infusion was immediately reduced by not more than 25% and thereafter at 10β20 min intervals until it was discontinued (that is, after three further decrements over about 1 hour). If any of the down-titrations of the initial infusion rate resulted in an alteration in MAP or HR of Β± 25%, the decrements were reduced and the down-titration was performed more slowly at the investigator's discretion. Open-label bolus doses of propofol or midazolam for sedation and fentanyl or morphine for analgesia could be given at the investigator's discretion to make the patient comfortable. Patients in the fentanyl and morphine treatment groups had their study regimens tapered for extubation at the investigator's discretion and in accordance with routine clinical practice at each study site.
Transition to routine sedation and analgesia after study day 5
Patients in the remifentanil treatment group who remained intubated and required sedation or analgesia after day 5 were transitioned to an alternative opioid/hypnotic regimen used routinely at the study site. Beginning within Β± 6 hours of completion of day 5, the remifentanil infusion rate was reduced in decrements of not more than 25% of the current rate at 20 min intervals in accordance with the clinical needs of the patient and the investigator's judgement. The down-titration of the remifentanil infusion was accompanied by the start of administration of an alternative opioid at a dose or rate considered appropriate for the clinical needs of the patient. Any infusion and/or bolus dosing with midazolam was maintained, although dose adjustments could be made at the investigator's discretion. If any down-titration produced a change in MAP or HR of Β± 25%, the size of subsequent decrements and the intervening time intervals were adjusted accordingly.
Patients in the fentanyl or morphine treatment groups who required sedation or analgesia beyond day 5 could either continue to receive their existing treatment or could be transitioned to an alternative regimen as considered appropriate by the investigator. If a patient was transferred to an alternative regimen, SAS, PI, MAP and HR values were recorded after all dose changes during the transitioning phase and at 30 and 60 min after discontinuation of the study drug(s).
Study endpoints
The primary efficacy endpoint was the overall between-patient variability around the mean time to neurological assessment. The overall mean time to neurological assessment was assessed as a secondary end point. Other secondary end points included the mean time to neurological assessment and the between-patient variability around that time during first to the fifth 24-hour assessment period, the mean percentage of hours of optimal sedation (SAS score 1β3), descriptive pain scores, weighted mean infusion rates of remifentanil, fentanyl, morphine, propofol and midazolam, the time from starting the extubation process until extubation, the time from extubation until ICU discharge, haemodynamics, and adverse events. At the end of the study, the physician or nurse involved were asked the following question: 'How would you rate the study drug regimen in terms of its overall quality of performance in facilitating wake-up (lightening the level of sedation) to allow neurological assessment of the patient?' Assessments were ranked as excellent, very good, good, fair or poor.
Statistical methods
For each set of neurological assessments made during the treatment period, the time from altering the infusion until completion of the assessment was evaluated. From these times, the mean log-transformed time to neurological assessment was calculated for each patient. The ratio of the variance of the mean log-transformed neurological assessment times was assessed by using two-sided F-tests overall and on each day of the study. In the original study design it was intended that between-patient variability and mean neurological assessment times would be compared for all patients. In the protocol if a 'successful' neurological assessment was not made within 6 hours of the first downward titration, it was planned that an imputed neurological assessment time of 6 hours would be used, the rationale a priori being that patients did not wake up due to drug accumulation. However, neurological assessments might not have been possible owing to treatment-independent deterioration in a patient's neurological condition. It was concluded therefore that an imputation strategy was inappropriate and an observed case analysis was considered to be the most useful way of analysing the data. The log mean times to neurological assessment were analysed by unpaired t-tests and back-transformed to geometric means and mean ratios. As well as an overall analysis of time to neurological assessment, assessments within each 24-hour period were made. The analysis of pain and sedation control was undertaken with the Wilcoxon Rank Sum test. Median differences and their 95% confidence intervals are also quoted. The recovery endpoints were analysed with Cox proportional hazards. Hazard ratios and their 95% confidence intervals are quoted. Cerebral dynamics were collected on only a subset of the patients. These data were analysed by using an analysis of variance with baseline entered as a covariate. The proportion of patients with the most common adverse events (defined as 5% or more of patients experiencing the adverse event from any treatment group) were tabulated by treatment group and analysed with Fisher's Exact Test.
A total of 160 randomised patients were required for the detection of a 54% reduction in the variance of the mean log-transformed wake-up times for the patients receiving remifentanil compared with the fentanyl or morphine treatment groups by using two-sided F-tests with 80% power and a 0.05 level of significance.
Results
A total of 161 patients were treated in this study (84 with remifentanil, 37 with fentanyl and 40 with morphine); patient characteristics and baseline clinical assessments are summarised in Table 2. The three groups were well matched for age, physical characteristics and baseline assessments of SAS, GCS, PI, MAP and HR. Most patients were receiving intensive care after intracranial surgery. As the study progressed the number of patients in each of the treatment groups reduced in a similar fashion, predominantly because patients were recovering during the first couple of days and were being extubated. Twenty-three patients received remifentanil for 5 days.
| Characteristic | Remifentanil | Fentanyl | Morphine |
|---|---|---|---|
| Number of patients treated | 84 | 37 | 40 |
| Mean age, years (SD) | 46.8 (16.3) | 49.6 (16.9) | 47.3 (20.0) |
| Sex | |||
| Male | 44 (52%) | 24 (65%) | 25 (63%) |
| Female | 40 (48%) | 13 (35%) | 15 (38%) |
| Mean height, cm (SD) | 171.1 (9.1) | 170.9 (7.4) | 170.9 (8.5) |
| Mean weight, kg (SD) | 76.5 (12.2) | 76.5 (12.6) | 75.2 (12.2) |
| Median duration of mechanical ventilation, days (range) | 1.95 (0.16β5.00) | 1.47 (0.08β5.00) | 1.70 (0.19β5.00) |
| Reason for admission to ICU | |||
| Subarachnoid haemorrhage | 19 (23%) | 7 (19%) | 12 (30%) |
| Isolated neurotrauma | 13 (15%) | 4 (11%) | 9 (23%) |
| Post-intracranial surgery | 31 (37%) | 18 (49%) | 10 (25%) |
| Epidural, subdural or intracranial haematoma | 16 (19%) | 6 (16%) | 6 (15%) |
| Cerebrovascular accidentsa | 3 (4%) | 1 (3%) | 2 (5%) |
| Other | 2 (2%) | 1 (3%) | 1 (3%) |
| Mean SAS score (SD) | 3.7 (1.5) | 3.6 (1.2) | 3.7 (1.5) |
| Mean GCS (SD) | 8.4 (2.7) | 8.8 (2.9) | 8.6 (2.5) |
| Mean Pain Intensity score (SD) | 2.1 (1.1) | 2.1 (1.0) | 2.1 (1.0) |
| Mean MAP, mmHg (SD) | 97.2 (17.6) | 100.6 (13.8) | 97.4 (14.1) |
| Mean heart rate, bpm (SD) | 89.3 (20.3) | 90.9 (20.5) | 88.9 (21.5) |
Efficacy
Overall, between-patient variability in the time to neurological assessments was significantly smaller when using analgesia-based sedation with remifentanil compared with hypnotic-based sedation with fentanyl or morphine; mean neurological assessment times were also significantly shorter with remifentanil-based sedation (Table 3). On average, neurological assessments could be completed 0.3 hours and 0.41 hours earlier, respectively (see Table 3 for differences between remifentanil and fentanyl/morphine on each of the five days of assessment). Mean neurological assessment times overall and for each of the five days are shown in Fig. 2.
Fentanyl and morphine treatment groups were optimally sedated (SAS scores 1β3) for a significantly longer duration during the treatment period (Table 4). Although statistical differences were observed against remifentanil, optimal sedation was, on average, achieved for all treatment groups in excess of 95% of the treatment period. There was no significant difference between any of the treatment groups with regard to the incidence of pain; on average, patients had no pain or mild pain for more than 99% of the treatment period.
Exposure to opioids and sedative agents is shown in Table 5. Remifentanil was administered for slightly longer than in the fentanyl and morphine treatment groups. Nearly all the patients required propofol and some patients received it for longer than the recommended 72 hours. There was a trend towards reduced propofol use in the remifentanil treatment group.
Remifentanil patients were extubated significantly earlier (about 1 h) than patients who were administered a hypnotic-based regimen that included morphine (P = 0.001, Table 6). This difference was not observed when comparing remifentanil with fentanyl. There were no observed differences between remifentanil and fentanyl or morphine in the time from starting the extubation process until ICU discharge.
Seventy-eight per cent of physicians or ICU nurses thought that the performance of remifentanil in facilitating 'waking' the patient up to allow assessment of neurological function was either very good or excellent. This compares with 25% for fentanyl and 8% for morphine (Fig. 3).
ICP and CPP were measured in only a relatively small number of patients and are summarised in Table 7. Mean baseline values were within normal physiological ranges and there were no significant differences between remifentanil and fentanyl or morphine during the treatment period. The weighted mean MAP was very similar across the three treatment groups. Mean (range) values were 73.0 (30.2β103.6), 71.0 (28.8β109.8) and 74.4 (26.2β123.7) mmHg for remifentanil, fentanyl and morphine, respectively. A similar situation was seen for HR, with respective values of 64.4 (20.0β109.6), 65.5 (22.1β105.3) and 66.6 (20.7β130.8) bpm.
Geometric mean time from altering the infusion until completion of daily neurological assessments.
Intensive care unit physician or nurse satisfaction score.
| Parameter | Overall | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 |
|---|---|---|---|---|---|---|
| Remifentanil | = 64n | = 58n | = 33n | = 26n | = 21n | = 20n |
| Mean time to neurological assessment,ha | 0.41 | 0.35 | 0.45 | 0.46 | 0.78 | 0.81 |
| Between-patient variability | 0.44 | 0.35 | 0.47 | 1.35 | 0.3 | 0.42 |
| Fentanyl | = 32n | = 32n | = 13n | = 11n | = 7n | = 8n |
| Mean time to neurological assessment,ha | 0.71 | 0.69 | 0.67 | 0.92 | 1.63 | 1.83 |
| Mean ratio (95% CI) | 1.74 (1.26, 2.41) | 1.98 (1.44, 2.72) | 1.48 (0.73, 3.01) | 2.01 (0.93, 4.33) | 2.09 (1.33, 3.30) | 2.27 (1.39, 3.73) |
| Remifentanil versus fentanyl | = 0.001P | < 0.001P | = 0.274P | = 0.074P | = 0.003P | = 0.002P |
| Between-patient variability | 0.86 | 0.86 | 3.01 | 0.51 | 0.13 | 0.1 |
| Ratio of variability (95% CI) | 1.96 (1.01, 3.45) | 2.45 (1.37, 4.79) | 6.41 (2.83, 19.9) | 0.38 (0.15, 1.34) | 0.45 (0.16, 2.61) | 0.24 (0.08, 1.16) |
| Remifentanil versus fentanyl | = 0.024P | = 0.003P | < 0.001P | = 0.109P | = 0.333P | = 0.059P |
| Morphine | = 34n | = 31n | = 20n | = 10n | = 3n | = 2n |
| Mean time to neurological assessment, ha | 0.82 | 0.79 | 0.7 | 1.01 | 1.28 | 1.86 |
| Mean ratio (95% CI) | 2.01 (1.44, 2.81) | 2.25 (1.60, 3.15) | 1.53 (0.93, 2.52) | 2.19 (0.98, 4.86) | 1.65 (0.84, 3.25) | 2.31 (0.87, 6.13) |
| Remifentanil versus morphine | < 0.001P | < 0.001P | = 0.091P | = 0.055P | = 0.139P | = 0.088P |
| Between-patient variability | 0.98 | 1.03 | 1.27 | 0.48 | 0.12 | 0.02 |
| Ratio of variability (95% CI) | 2.24 (1.28, 4.28) | 2.93 (1.63, 5.80) | 2.71 (1.27, 6.58) | 0.35 (0.14, 1.37) | 0.41 (0.13, 23.0) | 0.06 (0.02, 112.6) |
| Remifentanil versus morphine | = 0.006P | = 0.001P | = 0.012P | = 0.108P | = 0.659P | = 0.381P |
| Parameter | Remifentanil (= 84)n | Fentanyl (= 37)n | Morphine (= 40)n |
|---|---|---|---|
| Optimal sedation (SAS = 1β3) | |||
| Percentage hours, median (range) | 95.6 (15β100) | 98.1 (87β100) | 99.0 (0β100) |
| Median difference (95% CI) | -2.36 (-4.4, -1.0) | -2.30 (-4.2, -0.9) | |
| Pa | <0.001 | <0.001 | |
| No pain or mild pain | |||
| Percentage hours, median (range) | 99.3 (72β100) | 99.7 (79β100) | 99.2 (15β100) |
| Median difference (95% CI) | 0.0 (-0.5, 0.0) | 0.0 (-0.4, 0.3) | |
| Pa | 0.495 | 0.928 | |
| Moderate pain | |||
| Percentage hours, median (range) | 0.4 (0β28) | 0.0 (0β5) | 0.1 (0β9) |
| Median difference (95% CI) | 0.0 (0.0, 0.4) | 0.0 (0.0, 0.2) | |
| Pa | 0.154 | 0.647 | |
| Severe, very severe or worst possible pain | |||
| Percentage hours, median (range) | 0.0 (0β3) | 0.0 (0β1) | 0.0 (0β4) |
| Median difference (95% CI) | 0.0 (0.0, 0.0) | 0.0 (0.0, 0.0) | |
| Pa | 0.111 | 0.963 |
| Parameter | Remifentanil (= 84)n | Fentanyl (= 37)n | Morphine (= 40)n |
|---|---|---|---|
| Opioid | |||
| Median duration of opioid infusion, h (range) | 47.3 (3.8β120) | 35.2 (0.2β120) | 40.9 (4.5β120) |
| Median weighted mean opioid infusion rate: remifentanil and fentanyl, ΞΌg kgh; morphine, mg kgh(range)-1-1-1-1 | 15.4 (3.0β38.2) | 3.6 (0.1β7.9) | 0.1 (0.0β6.8) |
| Propofol | |||
| Number of patients who received a propofol infusion | 76 (90%) | 37 (100%) | 37 (93%) |
| Median duration of propofol infusion, h (range) | 24.3 (0.0β118) | 24.5 (0.0β119.4) | 41.7 (0.7β115.3) |
| Median weighted mean propofol infusion rate, mg kgh(range)-1-1 | 1.93 (0.2β68.8) | 2.49 (0.5β11.5) | 2.30 (0.3β18.1) |
| Midazolam | |||
| Number of patients who received a midazolam infusion | 30 (36%) | 11 (30%) | 12 (30%) |
| Median duration of midazolam infusion, h (range) | 47.3 (0β117.1) | 48.1 (2.3β112.1) | 22.4 (1.8β101.4) |
| Median weighted mean midazolam infusion rate, mg kgh(range)-1-1 | 0.18 (0β17) | 0.11 (0β2.3) | 0.13 (0.1β0.5) |
| Parameter | Remifentanil (= 47)n | Fentanyl (= 22)n | Morphine (= 28)n |
|---|---|---|---|
| Median time on mechanical ventilation during the treatment period, h (range) | 24.83 (12.5β110.2) | 24.08 (16.4β70.0) | 37.04 (17.8β98.2) |
| Hazard ratio relative to comparator | 1.21 | 0.71 | |
| 95% CI | 0.70, 2.10 | 0.43, 1.18 | |
| P | 0.5 | 0.188 | |
| Median time from the start of the extubation process until actual extubation, h (range) | 1.00 (0.0β97.2) | 0.68 (0.0β5.6) | 1.93 (0.0β96.2) |
| Hazard ratio relative to comparator | 1.23 | 0.42 | |
| 95% CI | 0.70, 2.13 | 0.25, 0.71 | |
| P | 0.474 | 0.001 | |
| Median time from the start of extubation process until ICU discharge, h (range) | 43.50 (2.4β150.0) | 42.90 (2.2β120.6) | 49.63 (3.7β144.2) |
| Hazard ratio relative to comparator | 1.34 | 0.98 | |
| 95% CI | 0.76, 2.37 | 0.56, 1.70 | |
| P | 0.316 | 0.928 |
| Parameter | Remifentanil (= 20)n | Fentanyl (= 10)n | Morphine (= 12)n |
|---|---|---|---|
| ICP | |||
| Mean baseline, mmHg (SD) | 11.7 (6.3) (= 16)n | 10.8 (8.1) (= 8)n | 16.7 (9.0) (= 10)n |
| LS mean, mmHg | 11.97 | 13.93 | 10.31 |
| LS mean differences | 1.95 | -1.66 | |
| 95% CI | -1.70, 5.60 | -5.22, 1.90 | |
| Pa | 0.285 | 0.351 | |
| CPP | |||
| Mean baseline, mmHg (SD) | 80.5 (9.1) (= 12)n | 85.5 (15.8) (= 5)n | 73.6 (17.6) (= 8)n |
| LS mean, mmHg | 68.77 | 75.58 | 76.99 |
| LS mean differences | 6.81 | 8.22 | |
| 95% CI | -8.13, 21.74 | -5.29, 21.72 | |
| Pa | 0.359 | 0.223 |
Safety
There were six deaths in this study, four in the remifentanil group, none in the fentanyl group and two in the morphine group. None of the deaths were considered to be related to the study drugs. Most adverse events reported in this study occurred during the maintenance phase of the treatment period (Table 8). No adverse events were reported during the follow-up period of the study. Adverse events leading to premature discontinuation from the study involved bradycardia, cerebral infarction, oedema, hypotension and intracranial haemorrhage in the remifentanil group, raised ICP in the fentanyl group, and bradycardia and raised ICP in the morphine group. Although the overall incidence of patients with adverse events seemed to be slightly higher in the remifentanil group, most of this involved isolated events and there was no significant difference between remifentanil and either of the comparator opioids in adverse events occurring in 5% or more of patients: these involved hypotension, bradycardia and polyuria. Serious adverse events occurred in 5% of patients in each treatment group (four remifentanil patients involving bradycardia, cerebral infarction, oedema or intra-cranial haemorrhage; two fentanyl patients involving cardiac arrest, hypotension or raised ICP; two morphine patients involving cerebral infarction, post-operative complication or raised ICP). There was only one drug-related serious adverse event involving bradycardia in a patient treated with remifentanil. This occurred in a 63-year-old male with a history of atrial fibrillation receiving remifentanil in combination with propofol for analgesia and sedation after spontaneous intracerebral (right temporo-occipital) haemorrhage. About 51 hours after starting the remifentanil infusion, the patient developed severe bradycardia (less than 50 bpm), considered to be life threatening. The remifentanil infusion was discontinued and the bradycardia resolved 20 min after the remifentanil infusion was stopped. The investigator considered there was a reasonable possibility that the bradycardia was caused by remifentanil, although the patient's concurrent atrial fibrillation was also cited as a possible cause of the event.
| Parameter | Remifentanil (= 84)n | Fentanyl (= 37)n | Morphine (= 40)n | ||
|---|---|---|---|---|---|
| Premature discontinuation from the study due to an adverse event | 6 (7%) | 1 (3%) | 2 (5%) | ||
| Patients with any adverse event | 32 (38%) | 9 (24%) | 12 (30%) | ||
| Patients with a drug-related adverse event | 21 (25%) | 3 (8%) | 4 (10%) | ||
| Number (%) of patients with any adverse event | |||||
| Treatment period | |||||
| Maintenance phase | 29 (35%) | 8 (22%) | 10 (25%) | ||
| Extubation phase | 2 (2%) | 0 | 0 | ||
| Post-extubation phase | 2 (2%) | 0 | 0 | ||
| Post-treatment period | 5 (6%) | 4 (11%) | 2 (5%) | ||
| Number (%) of patients with a serious adverse event | 4 (5%) | 2 (5%) | 2 (5%) | ||
| Number (%) of patients with a drug-related serious adverse event | 1 (1%) | 0 | 0 | ||
| Summary of adverse events occurring in 5% or more of patients | |||||
| Event | Remifentanil | Fentanyl | Morphine | Pa | Pb |
| Hypotension | 12 (14%) | 4 (11%) | 2 (5%) | 0.774 | 0.223 |
| Bradycardia | 5 (6%) | 2 (5%) | 2 (5%) | 1 | 1 |
| Polyuria | 3 (4%) | 2 (5%) | 0 | 0.641 | 0.55 |
Discussion
The present study was a comparison of sedation techniques, designed to compare an analgesia-based treatment regimen using remifentanil with conventional hypnotic-based sedative practice in patients with neurotrauma. In the analgesia-based treatment group the remifentanil infusion was started and titrated to response to provide optimal sedation and patient comfort before the administration of any sedative agent. In the hypnotic-based treatment group sedation and analgesia were started at the same time, with the sedative agent being predominantly titrated to provide patient comfort.
The study was complex in design and the reduction in sedation or wake-up process for neurological assessment was not specifically defined but was left up to the discretion of the investigator and local practice in each hospital. The study used two different sedative agents because it was considered normal clinical practice to change from propofol to midazolam for patients who are in the ICU for more than 3 days. This treatment regimen was based on the opinions of clinicians who were consulted during the development of the study design. Overall, remifentanil afforded significant reductions in mean neurological assessment times and between-patient variability around these times using a well-balanced group of patients. The reduced variability is indicative of better control of the patient's level of sedation and greater predictability in the offset of sedative effects when awakening the patient for neurological assessment. Reduced variability in the duration of optimal sedation has recently been reported by Muellejans and colleagues [15]. In a group of predominantly post-cardiac surgical ICU patients, it was suggested that the superior titratability of remifentanil results in a better quality of sedation for critically ill patients. The superior control of analgesia and sedation afforded by remifentanil is supported by the ICU physician or nurse satisfaction scores, in which remifentanil was considered to be either excellent or very good by 78% of the users; this was clearly differentiated from fentanyl and especially morphine, with scores of 25% and 8%, respectively.
Given that statistical differences were shown overall and at day 1, does this mean that remifentanil is only suitable for the first day of the patient's stay in the ICU? Even though 161 patients took part in this study, the lack of consistent differences between the treatment groups from day 2 onwards is probably a result of the diminishing number of patients. Hence the latter part of the study could only show trends (see Fig. 2) and did not have the power to demonstrate statistical differences.
It is clear that analgesia-based sedation was as effective as hypnotic-based sedation, with patients being optimally sedated (SAS score 1β3) for more than 95% of the treatment period. The largest median difference between remifentanil and the comparator opioids was -2.36% (Table 4), with a maximum of -4.4%. Although the median percentage of hours of optimal sedation was highly significantly different (P < 0.001), such a small difference is not likely to be clinically significant.
Rapid and predictable emergence from sedation is very important in patients with neurotrauma. Clinicians need to be able to assess their patient's neurological function rapidly; however, this is not always possible when using conventional hypnotic-based sedation because of the unpredictable elimination of conventional sedative and analgesic agents. The predictable, organ-independent metabolism of remifentanil, which is unaffected by impaired kidney and liver function, results in a rapid and predictable offset of action of remifentanil and eliminates 'hangover' sedation often experienced with conventional sedative and analgesic agents. Analgesia-based sedation with remifentanil therefore has the potential to reduce the need for additional procedures such as CT (computed tomography) scanning, to permit earlier detection of neurological deterioration and to allow neurosurgeons to make earlier decisions concerning the need for further operative procedures.
When remifentanil was first used in anaesthesia, post-operative pain occurred more frequently because of the rapid offset of effects. A change in the early treatment of post-operative pain relief was needed and as a result this problem should no longer occur [18]. In a double-blind study using remifentanil in the critically ill [15], pain after discontinuation of remifentanil has been reported. It is likely that the double-blind design of that study meant that pain transition could not be optimised. In the present open-label study doctors could proactively pre-empt pain by the administration of longer-acting analgesics well before stopping the remifentanil infusion, with the result of there being no difference in pain scores between remifentanil and the comparator opioids.
The median weighted mean dose of remifentanil observed in this study was slightly higher than that reported in previous studies [15,19,20]. In addition, in previous studies 43β78% of patients did not require administration of a sedative agent [15,19,20]. In the present study almost all the patients required propofol, and the median weighted mean dose of propofol was much higher than the mean value of about 0.5 mg kg-1 h-1 reported previously [15]. This observation might be due to the deeper level of sedation targeted in this study. Remifentanil interacts with all sedative agents in a synergistic manner. When using remifentanil-based sedation, the recommended starting dose of propofol is 0.5 mg kg-1 h-1 which is much lower than that used for hypnotic-based sedation. This is an important point to remember: if a 'normal' sedative dose of propofol (3 mg kg-1 h-1) is administered with the recommended starting dose of remifentanil, adverse sequelae such as hypotension might occur. The reduced number of patients from day 4 onwards makes it difficult to draw any conclusions about midazolam-sparing effects when using remifentanil.
The median weighted mean infusion rate of remifentanil was lower than 18 ΞΌg kg-1 h-1 and almost all the patients received propofol. This could have resulted in the sedative agent's being the rate-limiting agent during the periods of neurological assessment. Despite this, significant differences between treatment regimens were observed. To take full advantage of its unique properties, remifentanil must be started on its own and titrated to response before the addition of a sedative agent at a reduced dosage.
It has been reported that fentanyl, sufentanil and alfentanil can increase ICP [21,22], probably because of a vasodilatory response, secondary to systemic hypotension or changes in arterial PCO2, particularly in patients with hypovolaemia [23,24]. However, analgesia and sedation are often used to decrease ICP [25]. Although only measured in a small number of patients, baseline ICP and CPP values were within normal ranges and the physiological effect of remifentanil was not different from that observed with fentanyl or morphine.
The numerically higher incidence of adverse events in the remifentanil group might have been because of the open-label design of the study. Most of the adverse events were non-specific and it is important to note that there were no differences between the remifentanil and the comparator opioids in the frequency of adverse events occurring in 5% or more of patients. The most frequently reported adverse events were generally typical for opioids, with hypotension accounting for up to 45% of the number of patients reporting any adverse event. When hypotension occurred it was easily treated by routine clinical measures. In general, the systematic monitoring of the basic haemodynamic profile (MAP, HR, ICP, CPP) permitted remifentanil and propofol to be co-administered without sudden decreases in arterial blood pressure. Remifentanil has a potency similar to that of fentanyl [26]. Although not significantly different, the slightly higher incidence of hypotension in the remifentanil group is perhaps expected, given the higher dose of remifentanil administered.
Conclusions
The present study has demonstrated that the important clinical properties of remifentanil (such as rapid onset and offset of action, organ-independent metabolism and lack of accumulation) make it well suited for use in critically ill patients with neurotrauma. Analgesia-based sedation with remifentanil, titrated to response before the addition of any sedative agent, offered significantly faster and more predictable time to assessment of neurological function than a hypnotic-based technique. These data support the lack of accumulation and predictable offset of action of remifentanil. Both techniques were very effective in providing patient comfort and there was a trend towards less use of propofol in the remifentanil group. Although not seen when comparing remifentanil with fentanyl, there was a significantly shorter time to extubation compared with hypnotic-based sedation with morphine. Both techniques provided similar haemodynamic stability. There was a strong physician or nurse preference for use of remifentanil. Although data were limited, there was no evidence of any difference in ICP or CPP between remifentanil and the hypnotic-based treatment groups. Remifentanil was well tolerated in neurotrauma patients requiring intensive care for up to 5 days.
Key messages
In neurotrauma patients requiring intensive care for up to 5 days, analgesia-based sedation using remifentanil compared with a standard hypnotic-based technique provided the following:
β’ a significant reduction in the mean time taken to wake the patient for assessment of neurological function;
β’ a significantly reduced mean between-patient variability in the time to wake-up, making the performance of this assessment more predictable;
β’ a significantly shorter time to extubation than with a hypnotic-based regimen using morphine as the analgesic;
β’ no clinical differences in pain and sedation scores;
β’ a trend towards reduced dosing with propofol;
β’ comparable haemodynamic and cerebral haemodynamic stability;
β’ higher user satisfaction rating by physicians and nurses;
β’ a similar safety profile.
Competing interests
AK, KM, SS, AK, JS and BS received payment from GlaxoSmithKline (either personally or to their respective department) according to the number of patients recruited. AJTK is an employee of GlaxoSmithKline.
Abbreviations
bpm = beats per minute; CPP = cerebral perfusion pressure; GCS = Glasgow Coma Score; HR = heart rate; ICP = intra-cranial pressure; ICU = intensive care unit; MAP = mean arterial pressure; PI = Pain Intensity; SAS = SedationβAgitation Scale; SD = standard deviation.
Acknowledgments
Acknowledgements
We acknowledge the contribution of the following to the conduct of the study: in Austria, Professor Illievich (UniversitÀtsklinik f. AnÀsthesie und Allg. Intensivmedizin, Neurochirurgische Intensivmedizin, Vienna); in Belgium, Dr De Deyne (ZOL Campus St Jan, Genk), Dr Hantson (Clin. Univ. St. Luc, Brussels) and Dr Damas (CHR de la Citadelle, Liège); in Germany, Professor Wissing (J.-W. Goethe UniversitÀt, Frankfurt) and Professor Radke (Martin-Luther-UniversitÀt, Halle); in The Netherlands, Dr Maas (Academisch Ziekenhuis Rotterdam/Dijkzigt, Rotterdam) and Dr Punt (Atrium Heerlen Afdeling Anaesthesie, Heerlen); in Spain, Dr López (Hospital Infanta Cristina, Badajoz), Dr Bonome (Hospital Juan Canalejo, La Coruña), Dr Quero (Hospital Gregorio Marañón, Madrid) and Dr Sanchez-Isquierdo (Hospital 12 de Octubre, Madrid).
Contributor Information
Andreas Karabinis, Email: akarab@ath.forthnet.gr.
Kostas Mandragos, Email: mandragk@otenet.gr.
Spiros Stergiopoulos, Email: sstergio@med.uoa.gr.
Apostolos Komnos, Email: komnosap@otenet.gr.
Jens Soukup, Email: Jens.Soukup@medizin.uni-halle.de.
Ben Speelberg, Email: b.speelberg@elisabeth.nl.
Andrew JT Kirkham, Email: andrew.jt.kirkham@gsk.com.